BCL2 and hepatocellular carcinoma: Moreover, temsirolimus/vinblastine combination treatment specifically inhibits the expression level of survivin, Bcl-2, Mcl-1, etc., resulting in the occurrence of apoptosis and the decreasing of survival activity in HCC cells [334].